Loading…
Xeris Biopharma Holdings, Inc. is projected to rise to $8.80 by 2027, a +41% move from its current price of $6.23. XERS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.09 | $6.23 | $6.38 | +0.03% |
| May 30 | $6.03 | $6.23 | $6.44 | +0.05% |
| May 31 | $5.99 | $6.23 | $6.49 | +0.08% |
| Jun 1 | $5.96 | $6.24 | $6.53 | +0.10% |
| Jun 2 | $5.93 | $6.24 | $6.57 | +0.13% |
| Jun 3 | $5.90 | $6.24 | $6.60 | +0.15% |
| Jun 4 | $5.87 | $6.24 | $6.63 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.87 | $6.24 | $6.63 | +0.18% |
| Week 2 | $5.74 | $6.25 | $6.81 | +0.36% |
| Week 3 | $5.64 | $6.26 | $6.96 | +0.54% |
| Week 4 | $5.56 | $6.27 | $7.09 | +0.72% |
| Week 5 | $5.49 | $6.29 | $7.20 | +0.90% |
| Week 6 | $5.43 | $6.30 | $7.31 | +1.08% |
| Week 7 | $5.37 | $6.31 | $7.41 | +1.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
The company is incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. These products and development programs position Xeris within the healthcare sector, with a focus on endocrine and neurological therapies.
The description above outlines the asset’s product portfolio and corporate scope without reference to external entities, partnerships, or events beyond what is stated. The information reflects the company’s stated business lines and location as provided.
Xeris Biopharma Holdings, Inc. (XERS) trades with a current price of $6.19 and a market capitalization of $1.07B, ranking 2496 by market size. The stock sits within the Healthcare sector as a commercial-stage biopharmaceutical company with multiple approved and development-stage therapies.
In terms of the price outlook, the 2026 average price is $6.19 with a min of $5.29 and a max of $8.26, reflecting a neutral stance at the start of the forecast horizon. The forecast projects a bullish trajectory over the longer term, with notable upside by 2030 ($11.85 avg) and beyond, suggesting meaningful upside relative to the current level.
Overall, investors should consider that the asset’s near-term momentum reflects a neutral setup, while the longer-term forecast implies substantial upside potential anchored by rising average prices through 2030, 2040, and 2050.
A major floor 15.1% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 6.4% above — a clean break opens room to run.
A major ceiling 22.3% above — clearing it would confirm fresh momentum.
Key XERS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XERS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.26 | Sell | $6.23 | Sell |
| MA 10 | $6.23 | Buy | $6.23 | Sell |
| MA 20 | $6.26 | Sell | $6.21 | Buy |
| MA 50 | $6.01 | Buy | $6.20 | Buy |
| MA 100 | $6.45 | Sell | $6.38 | Sell |
| MA 200 | $7.13 | Sell | $6.38 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.93 | Neutral |
| Stoch RSI (14) | 35.93 | Neutral |
| CCI (20) | -15.87 | Neutral |
| Williams %R (14) | -56.34 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -4.59 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 43.66 | Neutral |
| TRIX (15) | 0.14 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 49.05 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 6.29 | Sell |
| ADX (14) | 8.87 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is bullish overall, with sentiment labeled as BULLISH and an RSI14 reading of 50. The near-term trend includes a 50-day simple moving average of $5.98 and a 200-day simple moving average of $7.14, offering a framework of nearby support and resistance.
Support is identified at $5.89 and resistance at $6.63, forming a trading band around the current level. The thirty-day price range spans from a low of $5.27 to a high of $7.27, illustrating modest volatility within the near term. Annualized volatility sits at 50%, indicating notable price movement potential for short-term trading.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.29 | $6.23 | $8.28 | 0% | Neutral | |
| $7.09 | $8.80 | $11.51 | +41% | Bullish | |
| $8.07 | $10.25 | $13.82 | +65% | Bullish | |
| $8.56 | $11.08 | $15.31 | +78% | Bullish | |
| $9.36 | $12.31 | $17.37 | +98% | Bullish | |
| $9.38 | $12.52 | $17.99 | +101% | Bullish | |
| $10.62 | $14.38 | $21.00 | +131% | Bullish | |
| $12.90 | $17.69 | $26.23 | +184% | Bullish | |
| $13.67 | $18.99 | $28.54 | +205% | Bullish | |
| $15.21 | $21.38 | $32.56 | +243% | Bullish | |
| $22.19 | $32.90 | $52.87 | +428% | Bullish | |
| $34.89 | $56.62 | $98.54 | +809% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.29 | $6.23 | $7.34 | +0.00% |
| June 2026 | $5.50 | $6.44 | $7.70 | +3.32% |
| July 2026 | $5.41 | $6.38 | $7.71 | -0.93% |
| August 2026 | $5.41 | $6.41 | $7.82 | +0.54% |
| September 2026 | $5.54 | $6.60 | $8.11 | +2.94% |
| October 2026 | $5.51 | $6.59 | $8.14 | -0.21% |
| November 2026 | $5.39 | $6.47 | $8.04 | -1.83% |
| December 2026 | $5.50 | $6.63 | $8.28 | +2.48% |
Click any year to see its month-by-month XERS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, XERS could reach as high as $8.28, with a base case around $6.23 and support toward $5.29 — roughly 0% from $6.23. A consolidation phase looks the most probable path here.
Expect XERS to range from $7.09 to $11.51 through 2027. The $8.80 average target implies a +41% move from current prices. That is up +41% on the projected 2026 average. Momentum favours further upside here.
The XERS price prediction for 2028 points to an average of $10.25 (low $8.07, high $13.82) — a potential gain of +65% on today's $6.23. Buyers look set to stay in control over this stretch.
In 2029, XERS is projected to trade between $8.56 and $15.31, averaging $11.08 — a potential gain of +78% from today's $6.23. That is up +8% on the projected 2028 average. Momentum favours further upside here.
Xeris Biopharma Holdings, Inc.'s 2030 outlook centres on $12.31, within a $9.36 to $17.37 range. That is up +11% on the projected 2029 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, XERS could reach as high as $17.99, with a base case around $12.52 and support toward $9.38 — roughly +101% from $6.23. Momentum favours further upside here.
Expect XERS to range from $10.62 to $21.00 through 2032. The $14.38 average target implies a +131% move from current prices. That is up +15% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The XERS price prediction for 2033 points to an average of $17.69 (low $12.90, high $26.23) — a potential gain of +184% on today's $6.23. Momentum favours further upside here.
In 2034, XERS is projected to trade between $13.67 and $28.54, averaging $18.99 — a potential gain of +205% from today's $6.23. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Xeris Biopharma Holdings, Inc.'s 2035 outlook centres on $21.38, within a $15.21 to $32.56 range. That is up +13% on the projected 2034 average. That marks a +243% change versus current levels. Momentum favours further upside here.
By 2040, XERS could reach as high as $52.87, with a base case around $32.90 and support toward $22.19 — roughly +428% from $6.23. Buyers look set to stay in control over this stretch.
Expect XERS to range from $34.89 to $98.54 through 2050. The $56.62 average target implies a +809% move from current prices. That is up +72% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in XERS today (≈ 160.513644 XERS) could be worth
$9,089.08
+$8,089.08 (+809%) by 2050 · US Dollar
Based on the average projected XERS price of $56.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XERSwould be worth at today's price.
$1,000 invested in XERS on May 27, 2025 (≈ 207.039341 XERS) would be worth
$1,289.86
+$289.86 (+29.0%) today · 1.29× · US Dollar
Based on a XERS entry price of $4.83 vs. today's $6.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.23 | $1,000 | -0.0% |
| 1 month ago | $6.12 | $1,017.97 | +1.8% |
| 3 months ago | $6.74 | $924.33 | -7.6% |
| 6 months ago | $7.18 | $867.69 | -13.2% |
| 1 year ago | $4.83 | $1,289.86 | +29.0% |
| All time (5.0y) ago | $3 | $2,076.67 | +107.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XERS forecast.
Our base-case forecast reaches $12.00 around 2030.
Implied market cap at $12.00: $2.07B
The multi-year forecast shows expanding upside, with the average price climbing across the forecast horizon and rising ROI. In 2026 the avg is $6.19 with a neutral sentiment, and by 2027 the avg extends to $8.67 with a 40% ROI, continuing through 2028 at $10.06 (62.5% ROI) and 2029 at $10.80 (74.5% ROI).
By 2030, the avg price is projected to $11.85 with a 91.4% ROI, and by 2031 the avg is $11.96 with a 93.2% ROI. The forecast accelerates further, with 2032 avg $13.72 (121.6% ROI), 2033 avg $16.75 (170.6% ROI), and 2034 avg $17.94 (189.8% ROI).
Longer-horizon projections show continued strength: 2035 avg $20.32 (228.2% ROI), 2040 avg $30.59 (394.3% ROI), and 2050 avg $51.90 (738.5% ROI). The sentiment remains BULLISH across the later years, indicating strong upside potential despite inherent uncertainty in forward forecasts.
These figures illustrate a path of substantial appreciation in the simulated price, alongside progressively higher ROI figures. As with all forecasts, outcomes are not guaranteed and depend on a range of market and company-specific factors that could influence actual results.
Tap a question to reveal the answer.
The 2030 forecast shows min $8.93, avg $11.85, max $16.90 with a 91.4% ROI and bullish sentiment.
The forecast shows bullish sentiment from 2027 onward with rising averages and positive ROI: 2027 ROI 40%, 2028 ROI 62.5%, 2029 ROI 74.5%, 2030 ROI 91.4%, continuing to 93.2% by 2031 and higher in later years.
Yes. The 2050 forecast lists an average of $51.90 and a max of $92.10, indicating potential to surpass $50 on the higher end.
The 2040 forecast shows min $20.28, avg $30.59, max $49.97 with a 394.3% ROI and bullish sentiment.
Current price is $6.19 and market cap is $1.07B.
Xeris Biopharma Holdings, Inc. Community Discussion
0Share your Xeris Biopharma Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.